Hikma Pharmaceuticals Plc (HIK) Receives Average Rating of “Hold” from Analysts

Hikma Pharmaceuticals Plc (LON:HIK) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is GBX 1,190 ($16.14).

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating on the stock in a research report on Thursday, November 9th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Hikma Pharmaceuticals in a report on Monday. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.85) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) price target on the stock in a report on Thursday, November 9th. Finally, lowered their price target on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating on the stock in a report on Friday, November 10th.

Shares of Hikma Pharmaceuticals (LON:HIK) opened at GBX 996.80 ($13.52) on Friday. Hikma Pharmaceuticals has a fifty-two week low of GBX 906.50 ($12.29) and a fifty-two week high of GBX 2,346 ($31.81). The firm has a market cap of $2,400.00 and a price-to-earnings ratio of 1,993.60.

COPYRIGHT VIOLATION WARNING: “Hikma Pharmaceuticals Plc (HIK) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/hikma-pharmaceuticals-plc-hik-receives-average-rating-of-hold-from-analysts.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply